Clinical Trial Update: A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma [Phase 1]

View source ↗

Summary

This clinical trial update reports on a Phase 1 pilot study evaluating the combination of pembrolizumab and lenvatinib as second-line treatment for advanced pan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Tumor, Adenocarcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING